Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 169
- 试验地点
- 17
- 主要终点
- Change From Baseline in Target Area Hair Count (TAHC) at Week 24
研究概览
简要总结
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 49 Years(Adult)
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Participant has androgenetic alopecia (AGA)
- •Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study.
排除标准
- •History of hair loss for reasons other than AGA
- •Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft
- •Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth
- •Hair-weaving within 6 months
- •Use of hair colorants or dyes within 6 months.
研究组 & 干预措施
Placebo
Two placebo tablets BID at 12-hour intervals for 24 weeks.
干预措施: Placebo (Drug)
Setipiprant
Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks.
干预措施: Setipiprant (Drug)
Finasteride
Finasteride 1 mg tablet, orally, once daily for 24 weeks.
干预措施: Finasteride (Drug)
结局指标
主要结局
Change From Baseline in Target Area Hair Count (TAHC) at Week 24
时间窗: Baseline (Day 1) to Week 24
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm\^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm\^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method.
Subject Self-Assessment (SSA) Score in Hair Growth at Week 24
时间窗: Week 24
The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method.
次要结局
未报告次要终点
